OCULIS HOLDING AG (OCS) Stock Price, Quote, News and Overview
NASDAQ:OCS - Nasdaq - CH1242303498 - Common Stock - Currency: USD
OCS Quote, Performance and Key Statistics
NASDAQ:OCS (5/14/2025, 4:05:12 PM)
17.28
-0.48 (-2.7%)
The current stock price of OCS is 17.28 USD. In the past month the price decreased by -3.63%. In the past year, price increased by 44.3%.
OCS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 52 | 678.34B | ||
| JNJ | JOHNSON & JOHNSON | 14.56 | 352.15B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 18.72 | 285.92B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 12.63 | 207.36B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 17.8 | 205.34B | ||
| MRK | MERCK & CO. INC. | 9.43 | 184.88B | ||
| PFE | PFIZER INC | 6.86 | 124.89B | ||
| SNY | SANOFI-ADR | 13.05 | 120.47B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.01 | 89.79B | ||
| GSK | GSK PLC-SPON ADR | 6.67 | 73.29B | ||
| ZTS | ZOETIS INC | 25.73 | 69.10B | ||
| HLN | HALEON PLC-ADR | 21.67 | 46.89B |
Related stock screener links
About OCS
Company Profile
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The company is headquartered in Zug, Zug and currently employs 49 full-time employees. The company went IPO on 2023-03-03. The firm is focused on the development of eye disease treatment for ophthalmology. The company includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The firm have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
Company Info
OCULIS HOLDING AG
Bahnhofstrasse 7
Zug ZUG CH
Employees: 36
Phone: 41588100182
OCULIS HOLDING AG / OCS FAQ
What is the stock price of OCULIS HOLDING AG today?
The current stock price of OCS is 17.28 USD. The price decreased by -2.7% in the last trading session.
What is the ticker symbol for OCULIS HOLDING AG stock?
The exchange symbol of OCULIS HOLDING AG is OCS and it is listed on the Nasdaq exchange.
On which exchange is OCS stock listed?
OCS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for OCULIS HOLDING AG stock?
12 analysts have analysed OCS and the average price target is 32.79 USD. This implies a price increase of 89.73% is expected in the next year compared to the current price of 17.28. Check the OCULIS HOLDING AG stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is OCULIS HOLDING AG worth?
OCULIS HOLDING AG (OCS) has a market capitalization of 811.12M USD. This makes OCS a Small Cap stock.
How many employees does OCULIS HOLDING AG have?
OCULIS HOLDING AG (OCS) currently has 36 employees.
What are the support and resistance levels for OCULIS HOLDING AG (OCS) stock?
OCULIS HOLDING AG (OCS) has a support level at 17.27 and a resistance level at 17.99. Check the full technical report for a detailed analysis of OCS support and resistance levels.
Is OCULIS HOLDING AG (OCS) expected to grow?
The Revenue of OCULIS HOLDING AG (OCS) is expected to grow by 7.32% in the next year. Check the estimates tab for more information on the OCS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy OCULIS HOLDING AG (OCS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of OCS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of OCS, evaluating the profitability, health, valuation and growth aspects
- OCULIS HOLDING AG (OCS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- OCULIS HOLDING AG (OCS) Sales and EPS estimates to see what analysts future expectations are.
- OCULIS HOLDING AG (OCS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- OCULIS HOLDING AG (OCS) Insider and Institutional Ownership to learn about the owners and their transactions.
- OCULIS HOLDING AG (OCS) Stock Chart to make your own analysis
- OCULIS HOLDING AG (OCS) Latest news and press-releases to stay up to date.
Does OCULIS HOLDING AG (OCS) stock pay dividends?
OCS does not pay a dividend.
What is the Price/Earnings (PE) ratio of OCULIS HOLDING AG (OCS)?
OCULIS HOLDING AG (OCS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.73).
What is the Short Interest ratio of OCULIS HOLDING AG (OCS) stock?
The outstanding short interest for OCULIS HOLDING AG (OCS) is 0.03% of its float. Check the ownership tab for more information on the OCS short interest.
OCS Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to OCS. When comparing the yearly performance of all stocks, OCS is one of the better performing stocks in the market, outperforming 86.3% of all stocks.
OCS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OCS. OCS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
OCS Financial Highlights
Over the last trailing twelve months OCS reported a non-GAAP Earnings per Share(EPS) of -2.73. The EPS decreased by -40.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -71.27% | ||
| ROE | -116.89% | ||
| Debt/Equity | 0.01 |
OCS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 88% to OCS. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 9.64% and a revenue growth 7.32% for OCS